On October 31, 2025, 4D Molecular Therapeutics, Inc. entered into a Collaboration and License Agreement with Otsuka Pharmaceutical Co., Ltd. Under this agreement, Otsuka gains exclusive rights to develop and commercialize the gene therapy 4D-150 for ophthalmological diseases in various markets including Japan and Australia. Otsuka will lead all regulatory and commercialization efforts while 4D Molecular continues its global Phase 3 clinical activities.
Company Information
Company
4D Molecular Therapeutics
Location
Emeryville, California, United States
About
4DMT is a late-stage biotechnology company developing durable, disease-targeted genetic medicines designed to transform treatment paradigms and deliver long-lasting benefits to patients. Its lead candidate, 4D-150, aims to become a backbone therapy for blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF agents through a single intravitreal injection, with Phase 3 development underway for wet age-related macular degeneration and a second indication in diabetic macular edema. The company’s second candidate, 4D-710, is the first known genetic medicine to achieve successful aerosol-based delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis.
EmeryvilleBiotechnologyHealth CareMedicalGeneticsTherapeutics